Vascular Biogenics Ltd. (NASDAQ:VBLT) shares traded up 2.7% on Tuesday . The company traded as high as $4.32 and last traded at $4.26, with a volume of 70,959 shares changing hands. The stock had previously closed at $4.15.

A number of research analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of Vascular Biogenics from a “sell” rating to a “hold” rating in a report on Thursday, July 14th. Piper Jaffray Cos. restated a “buy” rating and set a $14.00 price target on shares of Vascular Biogenics in a report on Tuesday, June 7th. Chardan Capital restated a “buy” rating on shares of Vascular Biogenics in a report on Tuesday, June 7th. HC Wainwright initiated coverage on shares of Vascular Biogenics in a report on Tuesday, June 28th. They set a “buy” rating and a $11.00 price target on the stock. Finally, Roth Capital reiterated a “buy” rating and issued a $22.00 target price on shares of Vascular Biogenics in a report on Thursday, June 9th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $16.50.

The company has a 50-day moving average of $4.13 and a 200 day moving average of $3.67. The stock’s market cap is $97.77 million.

Vascular Biogenics (NASDAQ:VBLT) last released its quarterly earnings results on Friday, May 13th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.21). Analysts expect that Vascular Biogenics Ltd. will post ($0.82) earnings per share for the current fiscal year.

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.